Cultivate and produce medical and recreational cannabis products. Operate a diverse portfolio of cannabis brands catering to various consumer needs. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 5% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $137.8M against $667.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.71. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Against everything we grade, CRLBF lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CRLBF’s sales are going backwards, and it closed last year at a loss. The road back runs through both.